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An interdisciplinary European group of clinical experts in the field of movement disorders
and experienced Botulinum toxin users has updated the consensus for the use of Botu-
linum toxin in the treatment of children with cerebral palsy (CP). A problem-orientated
approach was used focussing on both published and practice-based evidence. In part I of
the consensus the authors have tabulated the supporting evidence to produce a concise but
comprehensive information base, pooling data and experience from 36 institutions in 9
European countries which involves more than 10,000 patients and over 45,000 treatment
sessions during a period of more than 280 treatment years. In part II of the consensus the
Gross Motor Function Measure (GMFM) and Gross Motor Function Classification System
(GMFCS) based Motor Development Curves have been expanded to provide a graphical
framework on how to treat the motor disorders in children with CP. This graph is named
‘‘CPGraph Treatment Modalities – Gross Motor Function’’ and is intended to facilitate
communication between parents, therapists and medical doctors concerning (1) achievable
motor function, (2) realistic goal-setting and (3) treatment perspectives for children with
CP. The updated European consensus 2009 summarises the current understanding
regarding an integrated, multidisciplinary treatment approach using Botulinum toxin for
the treatment of children with CP.
ª 2009 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights
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The Consensus update 2009 presents a conceptual framework
for best practice in the use of Botulinum toxin (BoNT) in
children with cerebral palsy (CP). Since the first European
consensus table on Botulinum toxin for children with CP in
20061 basic research, clinical trials, new treatment strategies
and safety regards have evolved in the expanding field of CP
management. The aim of this updated, annotated, and tabu-
lated evidence report (Table 1) is to incorporate the recent
advances in knowledge into all sections of the earlier
consensus table. A comprehensive literature search in
PubMed (including MEDLINE, NLM Gateway, PreMEDLINE,
HealthSTAR, as well as publisher supplied citations) was
performed as described in the first European consensus1
including literature from June 2006 until June 2009. Previously
cited literature was only removed if there was more accurate
literature published on a topic or level of evidence could be
increased with new literature.
Besides literature enhancement, the updated European
consensus table is based on data from an extended number of
36 European treatment centres. The authors were able to draw
upon the combined experience of more than 280 treatment
years, more than 10,000 treated patients, and more than
45,000 treatment sessions to condense the knowledge in the
consensus table.
1.2. Essentials of 2009
(1) Changing the Paradigm from ‘‘Botulinum toxin’’ to
‘‘Activity is supported by Botulinum toxin’’: Activity is
supported by BoNT and vice versa: due to its mechanism of
action, BoNT only reduces muscle tone in the active, non
fibrotic, ‘‘non-contractured’’ part of the muscle. However,
by reducing tone in the muscle it allows stretch to be
applied, which is in itself a stimulus for muscle growth.
Activity, which means function, (e.g. dorsiflexion of the foot
during the gait cycle) is dependant on the agonistic activity
of a particular muscle (in this case tibialis anterior muscle).
BoNT supports the agonist’s activity by reducing muscle
tone and regulatory circuits of the antagonist (here triceps
surae muscle). To improve function, activity, participation
and development of a child with CP additional therapies
have to be included (see also Sections 3 and 4).
(2) ‘‘Safety and publicity’’: BoNT reflects all the benefits and
controversies of modern medicine: strong and ongoing
medical success as well as a fashion-driven presence onmass media presence, and headline catching criticism. Due
to the wide number of indications Pharm Allergan (Prepa-
ration Botox and Vistabel), Ipsen Pharma (Preparation
Dysport), Merz Pharmaceuticals (Preparation Xeomin)
and Solstice Neuroscience (Preparation Neurobloc/Myo-
bloc) have had to document the possibility of severe
systemic side effects in a ‘‘red hand letter’’ in Europe in June
2007 (download at: The German Federal Institute for Drugs
and Medical Devices (BfArM http://www.bfarm.de/), fol-
lowed by an FDA statement in February 2008 (http://www.
fda.gov), and a statement produced by Swissmedic (http://
www.swissmedic.ch) in June 2008. In September 2008 the
German BfArM published the conclusive statement that
currently ‘‘there is no evidence showing a causal connec-
tion’’ between the fatal outcome of 5 patients and their
prior treatment with Botulinum toxin.2 A follow-up state-
ment of the FDA was published in May 2009 stating that FDA
has notified the manufacturers of licensed Botulinum toxin
products of the need to strengthen warnings in product
labelling and that manufacturers have to develop and
implement a Risk Evaluation and Mitigation Strategy
(REMS) to provide more information regarding the risk for
distant spread of Botulinum toxin effects after local injec-
tion in the future.3 It rests in the hand of the treating
physician to be up to date on the ongoing safety and label-
ling discussions using the above mentioned health
agencies and their internet domains. Additional informa-
tion can be accessed at the European Medicines Agency
(EMEA: http://www.emea.europa.eu/).
The members of the consensus group are strongly
committed to emphasise the ongoing need for a careful,
unbiased and transparent documentation of any adverse
events in the children with CP who are treated with BoNT,
ideally stratified by GMFCS levels (see also Section 2.6).2. Sections 1–10
2.1. Cerebral palsy (section 1)
CP is the most common cause of spastic movement disorders
in children.4,5 Epidemiologic data has shown that with the
advanced care in neonatal medicine the incidence and
severity of CP in premature children of very low birth weight
in Europe6 and northern America7 is decreasing. Our
Table 1 – Updated European consensus table on the use of Botulinum toxin for children with cerebral palsy
Section Key areas – updated consensus Key literature – selected clinical studies and reviews
1 Cerebral palsy: epidemiology,
etiology phenomenology
Epidemiology
- CP is the most prevalent cause for motor disorders in childhood
- The socio-economic impact of CP is high
- The prevalence is 2–3 per 1000 live births
- The prevalence increases up to 100 per 1000 live births in extreme pre-
maturity
Clinical studies
 Epidemiological studies on CP6,7,84–87
Etiology
Time of lesion – lesion pattern
- 1stþ 2nd trimester – maldevelopments
- early 3rd trimester – periventricular leucomalacia (PVL), intraventricular
hemorrhage (IVH)
- late 3rd trimester – cortical-subcortical and deep
grey matter lesions
The motor disorder in CP involves supra-spinal motor centres, cortico-
spinal tracts, segmental spinal circuits and the musculo-skeletal system.
Reviews
 Actual classification of CP88–92
 Classification of cerebral lesions in CP acc. to MRI11,93
 Epidemiology94
 Definitions of dystonia, rigidity and spasticity in children95
 Pathophysiology on paediatric motor disorders96
 Musculo-skeletal aspects of CP97,98
Phenomenology
- Type (spastic, dyskinetic or ataxic CP)
- Distribution (bilateral or unilateral)
- Severity (GMFCS Level I–V)
- Comorbidity (e.g. epilepsy, mental retardation,
sensory impairment etc.)
2 Medico-legal and medico-
economical aspects
Medico-legal aspects
- Users should be familiar with the guidelines for registration of BoNT
applicable in their countries.
- Comprehensively explain the proposed therapy to parents and care-
givers and obtain written consent.
- Meticulously document treatment details including evaluation of func-
tional outcome.
- Enhance pharmaco-vigilance by rigorously reporting all adverse events
Clinical studies
 Socio-economic impact of CP99–102
 Off-label use in paediatrics103
 Off-label therapy in Germany104
Reviews
 Minimal acceptable standards of healthcare105
 BoNT is elemental part of spasticity treatment106
 Statement of the Society for Neuropediatrics107
 Social outcomes of children with CP108
3 Botulinum toxin, integrated
therapy (see also: Fig. 1: CPGraph
Treatment Modalities – Gross
Motor Function)
Therapeutic options should consider all dimensions of the International
Classification of Functioning Disability and Health (ICF of the WHO):
- Body structure
- Body function
- Activity
- Participation
- Environmental factors
Clinical Studies
 BoNT combined with other treatments ([II],21 [II],77 [II],109
[II],110 [II],111 [II],112 [II],69 [II],113 [II],114 [II],115 [II],116 [II],117 [II],118
[II],119 [II],120 [II],121 [IV]122)
 Evidence based treatment in CP ([V]123)
Integrative aspect
BoNT can be combined with all other treatment modalities, e.g.
- BoNTþ all modalities of functional therapy:
Physiotherapy, OT, speech therapy, constraint-induced movement
therapy (CIMT), robotic assisted therapy, etc.
- BoNTþ orthoses, casting, splinting
- BoNTþ intrathecal baclofen or other
pharmacotherapy
- BoNTþ surgical intervention
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Key therapists (in alphabetical order)
- Developmental Paediatrician
- Functional therapist (physiotherapy, occupational therapy etc.)
- Orthopaedic surgeon
- Orthotist
- Paediatric neurologist
- Rehabilitation specialist
Reviews
 WHO/ICF/CP68,124
 Therapeutic interventions in CP125,126
 Pharmacotherapy of spasticity125–127
 BoNT & physical therapy128–130
 BoNT & occupational therapy131
 BoNT & casting132
 CIMT in CP133
 Existing consensus1,98,134
 Minimal acceptable standards for healthcare105
 Effectiveness of therapy after BoNT24
 Effectiveness of casting, physical therapy interventions and
orthoses in CP135,136
otulinum toxin and common
dications
General considerations
- A developmental disorder needs an adaptive approach
to cope with the changing patterns that occur
during the course of development.
- During the time of the most rapid motor development, the reversibility of
any treatment option is of value.
- (The reduction of the M-response as a measure for the paralysing effect
of BoNT seems to be effected more readily in dystonic muscles compared
to spastic muscles.)
Clinical studies
 Spastic quadriplegia ([IV]137)
 Spastic pes equinus ([I],138 [II],139 [II],140 [II],141 [II],142 [II],77
[III],143 [IV],144 [IV]145)
 Crouch-gait/flexed-knee gait ([II],119 [IV]146)
 Adductor spasticity ([II],114 [II]147)
 Upper limb flexor deformity ([II],148 [II],149 [II],21 [II],117 [II],120
[II],116 [II],121 [III],150 [IV]136)
 Analgesic effects of BoNT therapy ([II],110 [IV]151)
 Quantification of the M-response in dystonic and spastic
muscles ([I],138 [IV]152)
Therapy goals should be established by consent prior to therapy, adapted
to:
- GMFCS or MACS (see also Section 3, 8, and the CPGraph Treatment
Modalities – Gross Motor Function)
- Focal, multifocal or multi-level approach
- Functional relevance may include improved mobility (function, activity,
participation), ease of care, prevention of deformity or pain
The therapy goals should address specific clinical problems and patterns
in paediatric lower and upper extremity spasticity (the following termi-
nology is used in the cited studies but is not seen as ‘‘up to date’’ by the
consensus group. The corresponding SCPE terminology is displayed in
parentheses:
- Spastic quadriplegia (bilateral spastic CP)
- Spastic pes equinus (unilateral or bilateral spastic CP)
- Crouch-gait, hip flexion (bilateral spastic CP)
- Adductor spasticity (bilateral spastic CP)
- Upper limb flexor deformity (unilateral or bilateral spastic CP)
- Amelioration of pain (unilateral, bilateral spastic, or dyskinetic CP)
Reviews
 Rehabilitation of children with CP153
 Clinical value of BoNT154
 Family-centred service for children with CP155
 On CP and BoNT156,157
 Cochrane review: BoNT as an adjunct to treatment in the
management of the upper limb158
 Cochrane review: treatment of lower limb spasticity in CP159
(continued on next page)
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Table 1 (continued)
Section Key areas – updated consensus Key literature – selected clinical studies and reviews
5 Dosage and dose modifiers of
Botulinum toxin therapya
Preparations
In children with CP the available preparations can not be exchanged with
a fixed ratio due to different pharmacokinetic and pharmacodynamic
characteristics (no conversion factors).
Physicians need to be aware of national/local licensing restrictions
Pharmacology
 Mechanism of action of BoNT Serotype A162–165 and Serotype
B166
Cautions
- dose per muscle should not be increased
- dose per site should not be increased
- number of muscles treated should follow the clinical need
- undertreatment should be avoided
- carefully calculation of total dose, see dose modifiers below
Dose ranges [U¼Units; kg bw¼ kilogram body weight]a
BoNT Serotype A
- Preparation BOTOX
range [U/kg bw] 1–20 (–25)
max total dose [U] 400 (–600)
range max dose/site [U] 10–50
- Preparation Dysport
range [U/kg bw] 1–20 (–25)
max total dose [U] 500–1000
range max dose/site [U] 50–250
- Preparation Xeomin (adult studies suggest dosage equivalence with
Botox,160, 161 but for children this needs to be confirmed)
range [U/kg bw] not established yet
max total dose [U] not established yet
max dose/site [U] not established yet
BoNT Serotype B
- Preparation Neurobloc (mainly used as second line preparation in adult
neurology in case of secondary non-response to BoNT/A)
range [U/kg bw] not established
max total dose [U] not established
max dose/site [U] not established
Clinical studies
 Preparation Botox
 4 U Botox/kg body weight (pes equinus) ([I]138)
 20–30 U Botox/kg body weight (multi-level, multi-muscle
approach) ([IV],33 [IV]167)
 Dilution of 1–4 ml/Vial preparation Botox ([III]41)
 Preparation Dysport
 15–30 U Dysport/kg body weight (pes equinus, adductor
spasticity) ([II],77 [II],114 [I]168)
 Dilution of 1–5 ml/Vial preparation Dysport ([II]169)
 Preparation Neurobloc
 Up to 400 U Neurobloc/kg body weight in a small pilot
study ([IV],170 [IV]171)
 Low versus high dosage (upper and lower limb) ([I],168 [II],150
[II],172 [III]52)
 Dosage in multi-level treatment ([V],34 [II],69 [V],33 [IV]51)
 Dose modifiers39
Dose modifiers
- Severity of CP according to GMFCS
- Accompanying diagnoses (e.g. dysphagia, aspiration pneumonia,
hypopnea)
- Predominant type of movement disorder (spastic versus dyskinetic),
- Activity of the injected muscle (dynamic versus fibrotic compounds of
the muscle)
- Muscle bulk size
- Nutritional status, body mass index
- Knowledge about the distribution of motor endplates in the injected
muscle
- Experience from previous BoNT injections
Reviews
 Pharmacology of Botulinum Toxins173
 Physiological effects of BoNT in spasticity174
 Dose ranges:
 Up to 16 U Botox/kg bw39
 Up to 23 U Botox/kg bw20
 Up to 25 U Dysport/kg bw175
Dilution can be adapted to body region and muscle size (e.g. forearm:
lower dilution, lower leg: higher dilution).
Internet sources
 BoNT dosing tables: http://www.mdvu.org/(Login required)
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6 Safety of Botulinum toxin Three types of adverse events:
(1) Focal adverse events
- Local weakening beyond the therapy goal can occur when muscle size,
dosing guidelines and dilution guidelines are not respected or when
inadequate localisation techniques are applied.
- Distant adverse events (e.g. bladder dysfunction) can be observed when
dosing and dilution guidelines are neglected or inadequate localisation
techniques are applied.
(2) Generalised adverse events
- Generalised weakness has been observed and reported and can occur
when preparation specific dosage and dilution guidelines are not
respected.
(3) Procedural adverse events
- Haematoma (rare when small 27–30 gauge needles are used).
- No reports on local infections following BoNT injections have been
published or reported by the users of BoNT.
- procedural complications due to analgo-sedation or general anaesthesia
Specific risks of mortality and morbidity according to GMFCS need to be
addressed in future evaluations 54
Clinical studies safety
 Report on the safety and occurrence of adverse events after
repeated injections (preparation Dysport)176
 Report on adverse events in severe CP after repeated injec-
tions (preparation BOTOX) ([V]54)
 Report on safety of treatment and frequency of adverse
events in large cohort (preparation BOTOX) ([IV]33)
 Report on safety of treatment with high-dose BoNT/A
(BOTOX) ([IV],51 [IV],50 [IV],52 [IV]53)
 Safety profile of BoNT/A treatment in children (preparation
Dysport)42
 Report on dysphagia after BoNT/B ([V]177)
 Secondary non-response after repeated injections (BoNT/B)
([V]178)
 Accuracy is relevant for the safety of treatment ([II]21)
 Case-report on systemic effect of BoNT ([V]54)
 Report on the safety and adverse effects of BoNT/A, both
BOTOX and Dysport, in children below 2 year of age ([IV]47)
Reviews
 Meta-analysis on safety, incl. data from adults and children43
 Safety of long-term use44
 Safety of BoNT-A49
7 Botulinum toxin therapy and
procedures
Administration by an experienced team in a setting appropriate for
children
-The therapy setting has to be adapted according the patients needs
-adequate analgesia (in combination with sedation if necessary)
- Technique of injection (sonography, electrical stimulation, EMG)
Clinical studies procedure
 Accuracy of palpation/electrical stimulation59,66
 BoNT injection using sonography60,67
 Sonography-guided psoas injection61,65
 Repeated injections without general anaesthetic179
 N2O in paediatric patients56,57,180,181
Reviews
 EMG, pro/contra182,183
 Management of pain and anxiety184
 Methodology of sonography-guided injection62,64
8 Assessment and evaluation of
treatment with BoNT in children
with CP
Documentation and evaluation should use validated methods (according
to ICF/WHO).
Validity and reliability
 Joint Range of Motion185,186
 Ashworth Scale187,188
 Tardieu Scale188,189
 QEK, Deep-tendon reflexes, Clonus139
 GMFM14,15,190,191
 GAS192–194
 Video documentation,195 Edinburgh Visual GAIT,196,197
Physician Rating Scale, Observational Gait Scale198
 PEDI,199 BFMF,200 MACS201,202
 AHA: Assisting Hand Assessment,203 Melbourne Assess-
ment204–206
 Longitudinal health outcome,207 Health-related quality of
lifeb208–210
(continued on next page)
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Table 1 (continued)
Section Key areas – updated consensus Key literature – selected clinical studies and reviews
Body structure/function e.g.:
- Range of motion (ROM)
- (modified) Ashworth Scale [(M)AS)]
- Tardieu Scale
- Quantitative Electromyographic Kinesiology (QEK)
- Deep-tendon reflexes
- Clonus
- 3D gait analysis
- Video documentation
- Goal Attainment Scale (GAS)
Clinical Studies containing BoNT intervention
 ICF in CP ([III]124)
 Ashworth Scale ([III]187), Tardieu Scale189
 SMS, QEK, Deep-tendon reflexes, clonus ([II]139)
 GMFM ([II],139 [II]119)
 GAS ([IV],211 [IV],212 [II]21)
 Energy cost ([II]118)
 Video documentation, Edinburgh Visual GAIT ([II]118), Obser-
vational Gait Scale ([I]138), PEDI ([II],120 [II]213), COPM ([II],21
[II]120)
 Melbourne Assessment ([II]120), QUEST ([II],21 [II]120)
 3D gait analysis ([II],69 [IV],214 [III],70 [IV]71)
 3D kinematics in upper limb ([V]215)
 VAS ([IV]216)
Activity/participation e.g.:
- 3D gait analysis
- 3D kinematics in upper limb
- Gross Motor Function Measure (GMFM)
- Manual Ability Classification System (MACS)
- WeeFIM (Functional Independence Measure)
- Paediatric Evaluation of Disability Inventory (PEDI)
- Canadian Occupational Performance Measure (COPM)
- Child Health Questionnaire (CHQ)
- Quality of Upper Extremity Skills Test (QUEST)
- Melbourne Assessment of unilateral upper limb function
- Bimanual Fine Motor Function (BFMF)
- AHA (Assisting Hand Assessment)
- Physician Rating Scale, Observational Gait Scale
- Edinburgh Visual Gait Analysis Interval Testing Scale
- Energy expenditure measures
- Goal Attainment Scale (GAS)
- Visual Analogue Scale (VAS)
Caregiver Priorities & Child Health Index of Life with Disabilities
(CPCHILDª) questionnaireb
Reviews
 ICF approach68
 Evaluating therapy217–219,133
 Measures for muscles and joint in lower limb220
 Systematic literature review of assessment measures221
 Review of spasticity assessment measures222,188
 Review of measurements of activity level223
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9 Botulinum toxin therapy
adherence
Continuation
 Improved function
 Improved balance/posture
 Improved pain and comfort
 Crucial factors for treatment success:
- Number of treatments (although repeated treatments are successful, the
largest functional improvement usually occurs after the first treatment)
- dosages (different dosages may produce different levels of response
- Follow-up care (combination with functional therapy, orthotic manage-
ment, casting) seems crucial for a good result
- Age (younger children seem to respond better)
- Functional level (can influence a positive outcome)
- Individualised treatment approach with respect to muscle selection
Clinical studies
 Antibody screening in children with CP (mouse protection
bioassay) ([II]78)
 Antibody screening in children with CP (mouse hemi-
diaphragm assay,80,178 [V])
 Rate of antibody formation for BoNT (preparation BOTOX) in
adults81
 Long-term use ([IV],224 [II],213 [II]225)
 Why children discontinue treatment79
Discontinuation
 Continued benefit without further injections
 No significant gain or unacceptable side effects
 Secondary non-response
 Fibrosis
 Neutralizing antibodies against BoNT
 Continuation to orthopaedic treatment, intrathecal baclofen, or others
10 Research challenge CP (1) Evaluation of injection techniques and follow-up:
- Effect of BoNT within the muscle
- dilution, distribution, spreading within the muscle
- location of injection sites
- motor endplate targeting
(2) Evaluation of patient and treatment characteristics of high and low
responders.
(3) The effects of BoNT in combination with a goal directed therapy and
follow-up care.
(1) Follow up: Muscle biopsy substantiates longterm MRI
alterations one year after a single dose of Botulinum toxin
injected into the lateral gastrocnemius muscle of two
healthy volunteers. 226
(3) Activity focused and goal directed therapy for children with
cerebral palsy. 227
Level of evidence in parentheses behind clinical trials: I–V according to AACPDM Methodology to Develop Systematic Reviews of Treatment Interventions (Revision 1.2) 2008 Version83:
I¼ systematic review of randomized controlled trials (RCTs), Large RCTs (with narrow confidence intervals; n> 100).
II¼ smaller RCTs (with wider confidence intervals; n< 100), Systematic reviews of cohort studies, ‘Outcomes research’ (very large ecological studies).
III¼ cohort studies (must have concurrent control group), systematic reviews of case–control studies.
IV¼ case series, cohort study without concurrent control group, case–control study.
V¼ expert opinion, case study or report; bench research, expert opinion based on theory or physiologic research, common sense/anecdotes.
Citations are sorted chronologically, alphabetically and by level of evidence, if possible.
a Dose rests in the hand of treating physician (read carefully Sections 2, 4, 6).
b CPCHILD Questionaire to be downloaded at http://www.sickkids.ca/Research/CPCHILD-Questionaire/CPCHILD-Project/CPChild-questionaire/index.html.
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the disease has been greatly advanced by the development of
Magnetic Resonance Imaging techniques, which allow the
identification of the underlying structural changes in the
brain8,9 and gives information on topography and the extent
and potential timing of the causative lesion.10,11 Although the
cerebral lesion in CP is viewed as caused by a single event, CP
has to be understood as a developmental disorder described
over time as an individual develops. The development of the
European consensus on CP definition and classification12 and
its illustration by a video-based manual (the Reference and
Training Manual of the SCPE) provides a practical basis for
a unified approach with respect to diagnosis.13 A whole body
approach to classification (and reclassification) is facilitated by
the use of the Gross Motor Function Classification System
(GMFCS), which describes both disease severity and course.14,15
Reclassification of a child is recommended during every
appointment, especially when the child is under the age of four
years. Classification according to GMFCS may also be used for
decision-making concerning which treatment intervention is
appropriate over the course of time (see also Section 3). The
GMFCS classification system is a useful tool for hip surveillance
programs as was shown by a Swedish group in 2007.16 Classi-
fications by GMFCS and ‘limb distribution’ or by GMFCS and
‘type of motor impairment’ are significantly correlated.17
However, an analysis of function (GMFCS) by impairment (limb
distribution) indicated that the limb distribution did not add
prognostic value over GMFCS, although classification of CP by
impairment level seems useful for clinical and epidemiological
purposes.17,18 These recommendations are in line with a
report on the definition and classification of cerebral palsy as
published by an international consensus group.19
2.2. Medico-legal and medico-economical aspects
(section 2)
BoNT treatment of children with CP is often performed under
unlicensed conditions, using dosages and body segments or
muscles which are not supported by the relevant licensing
bodies. However, the off-label use of medications is accepted
and common practice in many paediatric fields and will
continue until there is a significant increase in research
directed at children. Typically the licences for BoNT treatment
show a great variety between countries (in Europe and all
other continents) and are restricted to specific preparations,
specific indications and dose limitations. Licensing does not
reflect the clinical need, especially for children with CP. Indi-
vidualised variations in BoNT dosage, BoNT dilution, clinical
indication(s) and the muscle group(s) treated represent
appropriate, although unlicensed, use where such treatment
is in line with clinical experience.20 A strong level of phar-
maco-vigilance is required due to the broad spectrum of
indications ranging from single muscle injections in children
with e.g. unilateral CP, GMFCS Level I versus multi-level
injections in severely affected children with bilateral CP,
GMFCS Levels III–IV (-V) suffering from multiple additional
impairments. In order to assess adverse events sufficiently,
a new system of pharmaco-vigilance documentation in the
field of off-label use was addressed by the NIH to be developed
for the future. In conclusion, careful decision-making ondosage, dilution and injection control rests in the hands of the
treating physician and has to be adapted to the individual
patient (see Sections 2.5 and 2.6).
2.3. Botulinum toxin and integrated therapy (section 3)
The use of BoNT in children with CP represents a major
therapeutic intervention but should never be considered as
a stand-alone treatment. The treatment approach to the
spastic movement disorders associated with CP must include
the whole range of conservative and surgical strategies and
regularly requires an interdisciplinary multi-modal team
approach. Recent developments in the field show that the
advanced use of BoNT i.e. combined with different conserva-
tive (or non-conservative) treatment options, has the potential
to achieve functional benefits for children with CP.21–23
However, there is insufficient evidence to either support or
refute the use of these interventions before or after BoNT
injections.24
A combination of therapy procedures is common in daily
practice, but addressing this by research is far from being
easy. Robotic assisted therapy can serve as an intervention
model where activity parameters can be measured during
therapy intervention.25–30 This may allow a better under-
standing about the correlation of effect of dosing to activity
and whether this has any effect on participation.
2.4. Botulinum toxin and common indications (section 4)
Spastic movement disorders in children with CP are a result of
the involvement of the brain, central motor pathways, spinal
circuits and musculo-skeletal system. With ongoing child
motor development spastic movement disorders develop into
distinctive motor patterns, which need to be recognised and
should be used to guide treatment. Starting in the 1990s an
increasing number of ‘‘focal’’ indications emerged such as pes
equinus, pes equinovarus, knee and hip flexion spasticity,
adductor spasticity, and spasticity of the upper extremity (e.g.
finger flexion, wrist flexion, ulnar deviation, elbow flexion,
and shoulder adduction). In a non-focal condition such as CP,
a number of muscle groups may need to be targeted.31,32 This
has led to the development of a multi-muscle, multi-level
treatment approach, in which a number of overactive muscle
groups are treated with BoNT to achieve an improvement of
limb motion and posture.33,34 The use of classifications, e.g.
for sagittal gait patterns31 may facilitate the development of
more standardized pattern-guided treatment approaches.
2.5. Dosage and dose modifiers of Botulinum toxin
therapy (section 5)
To date two preparations of BoNT Serotype A – Botox
(Allergan Inc.) and Dysport (Ipsen Ltd.) – have demon-
strated focal efficacy and functional gains for children with
CP. A third BoNT/A preparation (Xeomin, Merz Pharma,
Germany) was introduced to the market in 2005 with anec-
dotal reports on beneficial effect in children with neuro-
paediatric indications.35 All Botulinum toxin products are
distinct concerning their molecular structure and
manufacturing process and methods used for determining
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these pharmacological differences have significant implica-
tions for clinical use. Individual dosages must be calculated
independently for each BoNT preparation and fixed dose-
conversion factors are not applicable in the treatment of
spasticity in children with CP.3,33,39
Dosage calculation for each preparation is based on: (1)
total units per treatment session, (2) total units per kg body
weight per session, (3) units per muscle, (4) units per injection
site, (5) units per kg body weight per muscle (U/kg/muscle). It
has to be respected that the term ‘‘Unit’’ represents a different
biologic potency for each BoNT preparation.
Additional dose modifiers which have to be considered
when planning the injection protocol may be: severity of CP
according to GMFCS, accompanying diagnoses (e.g. dysphagia,
aspiration, breathing problems), predominance of movement
disorder (spasticity, dystonia), activity of the injected muscle,
muscle size, dynamic versus fibrotic muscle, knowledge about
the distribution of motor endplates in the injected muscle,
and experience from previous BoNT injections. Dilution will
depend on body region and muscle size (e.g. forearm versus
upper leg). In animal models higher dilutions showed greater
dissemination,40 but clinical evidence to support this infor-
mation is missing.41
2.6. Safety of Botulinum toxin (section 6)
BoNT therapy has been widely used for over 20 years during
which time it has proved to be a safe treatment option.33,42–49
In general, the occurrence and severity of CP adverse events
are rare. With the development of the multi-level treatment
strategy over the last years it has become apparent that an
adequate focal treatment effect can only be achieved when
the injected dose/muscle remains the same.34 Consequently,
the total dose/session increases with the number of treated
muscles, but this needs to be differentiated from ‘‘overdosing’’
a single muscle. Adverse events can be differentiated into
focal (local, distant), generalised and procedural adverse
events. With the development of the multi-level treatment
strategy a dose dependency of adverse events is discussed50
although this observation could not be supported by other
groups.51–53
Heightened interest concerning safety has occurred since
severe adverse events (deterioration in respiratory and oro-
motor function) were reported in a child with CP after BoNT
treatment (see introduction).54 With the report of severe
adverse events to national health institutions a so-called
‘‘red hand letter’’ was published in Germany by the German
Federal Institute for Drugs and Medical Devices (BfArM,
http://www.bfarm.de/) on June 1, 2007.55 In the United States
the national non-profit ‘‘Public Citizen’’ interest Organisa-
tion followed with a petition in January 2008, insisting on
transparency of Botulinum toxin treatment in the USA
(http://www.citizen.org/publications/release). Following this
petition a warning was issued by health institutions from
several countries: the Food and Drug Administration (FDA,
http://www.fda.gov) in the USA, Health Canada (http://www.
hc-sc.gc.ca) and by the Swiss Agency for Therapeutic Prod-
ucts (www.swissmedic.ch) in Europe 2008. In September
2008 the BfArM published a conclusive statement thatcurrently ‘‘there is no evidence showing a causal connec-
tion’’ between the fatal outcome of five reported patients in
Germany and their prior treatment with Botulinum toxin.2
The ongoing discussion concerning safety and licensing of
BoNT needs to be followed carefully by each treating
physician using the websites of the above mentioned health
institutions. It is important to emphasise that it remains the
responsibility of the treating physician to ‘‘check and
balance’’ dosing, dose modifying effects and procedural risks
(as general anaesthesia) for each child on an individual basis
keeping in mind the treatment goal(s), national and insti-
tutional rules. The GMFCS helps to anticipate severity-
related co-morbidities which should be taken into account
in every BoNT treatment session. According to the Surveil-
lance of Cerebral Palsy in Europe the GMFCS was distributed
at Level I in 32%, Level II in 29%, Level III in 8%, Level IV in
15%, and Level V in 16%. Learning disability was present in
40%, epilepsy in 33%, and severe visual impairment in 19%
of the children. More severe GMFCS levels correlated with
larger proportions of accompanying impairments18 and
a greater incidence of brain stem pathology and cranial
nerve dysfunction, that needs to be assessed prior to BoNT
treatment. The potential additional risk for the different
subgroups of GMFCS evolving from treatment with BoNT
remains to be clarified and is currently under investigation
in different centres worldwide.2.7. Botulinum toxin therapy and procedures (section 7)
In children with CP, pain management is an important issue.
Procedural pain such as BoNT injections requires appropriate,
effective analgesia, especially because BoNT therapy requires
repeated multiple, painful, but elective injections. Therefore,
appropriate, effective analgesia and as the case arises in
combination with sedation is a fundamental and an ethical
necessity. The optimal regimen will vary between individuals
and will be influenced by the age of the child, the GMFCS, the
number of muscles to be treated and the institutional setting
and resources.56,57 The procedural pain management includes
pharmacological as well as non-pharmacological techniques
and already starts prior to the procedure. Useful comprehen-
sive guidelines can be found at the webpage of The Royal
Australasian College of Physicians Sydney (http://www.racp.
edu.au/page/health-policy-and-advocacy/paediatrics-and-child-
health).58 Children should receive injections delivered using
an accurate localisation technique.21,59 Classical neurophysi-
ological localisation methods (EMG, electrical stimulation)
have recently been fine-tuned and amended by sonography
which allows precise identification of any target muscle using
readily available, non-invasive equipment.60–672.8. Assessment and evaluation of treatment with BoNT
in children with CP (section 8)
The development of new CP assessment tools has been
stimulated by the therapeutic possibilities offered by BoNT
therapy. Purpose-built classification tools and standardized
clinical assessments enable people to speak the same
language and to evaluate interventions using consistent and
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national classification of functioning, disability and health
(ICF).68 The cited literature in the table represents an excerpt
of the assessment and evaluation tools for treatment with
BoNT in children with CP. A large number of studies in
literature report about the effect of BoNT predominantly
only on the level of body structure and function (e.g. Ash-
worth and/or, Tardieu scores and Range of Motion). Gait
analysis data provide important information for delineating
the problems of children with CP.23,69–71 With respect to
study design, attempts are necessary to further improve the
quality to allow meta-analysis of studies. The following
issues are important: (1) Stratification of patients according
to age, Gross Motor Function/Manual abilities and type/
characteristic of movement disorder, (2) randomization
centrally organized, independent from the physician doing
the intervention, (3) Blinded rating of treatment effects, e.g.
through blinded video analysis in conjunction with appro-
priate outcome measures, (4) standardization of co-inter-
ventions, (5) intention-to-treat analysis of drop-out patients.
Qualitative research which aims to make sense of, or
interpret experiences of individuals,72–75 and aids in evalu-
ating the complexity of evidence-based clinical decisions76
will also be valuable.2.9. Botulinum toxin therapy adherence (section 9)
In a randomized controlled clinical trial 48% of children
treated with BoNT showed clinical improvement of initial
foot contact using a video gait analysis compared to 17% of
placebo treated children.77 A multicenter open label clinical
trial enrolling 207 children with CP showed an improvement
of dynamic gait pattern on the Physician Rating Scale in 46%
of patients (86/185) at first follow-up. BoNT injections (4 U/
Kg, Botox) were given approximately every 3 months. The
mean duration of BoNT/A exposure was 1.46 years per
patient and the response was maintained in 41–58% of
patients for 2 years.78 Initial reports on long-term adherence
show that, while about 75% of patients achieve their treat-
ment goals following the initial injection sessions, a consid-
erable number discontinue therapy for various reasons.79
Further research will need to delineate and quantify what
factors determine continuation or discontinuation of
therapy.
Non-responsiveness to BoNT can occur as a result of (i)
insufficient injection accuracy, (ii) predominant muscle
fibrosis or (iii) the formation of antibodies. In children under-
going BoNT treatment in the 1990s up to 30% were reported to
develop antibodies.80 Although higher dosages per session
have recently been administered to children with CP,
secondary non-response due to the presence of antibodies is
no longer experienced as a clinically relevant problem due to
the use of reformulated BoNT.23,33 This is in line with reports
that have demonstrated reduced antigenicity of the reformu-
lated preparation in adults with cervical dystonia.81 In
conclusion antibody formation does not seem to affect clinical
decision and any ‘‘new’’ BoNT formulations that are intro-
duced would have to prove their superiority to established
preparations.822.10. CP is a research challenge (section 10)
A sample of three exemplary research topics addressing some
clinical aspects of BoNT treatment with the multi-modal
treatment concept are named to stimulate future work.3. Part II: introduction of the CPGraph
treatment modalities – gross motor function
3.1. The need and chance for visualisation
A further development of this updated consensus table is the
introduction of an integrative treatment graph for children
with bilateral spastic cerebral palsy (CPGraph Treatment
Modalities – Gross Motor Function (Fig. 1)).
This graph was presented as a draft and discussed at the
consensus meeting and has been adapted on the basis of vivid
discussions. It represents the likely path of motor develop-
ment in a group of children with bilateral spastic CP based on
the GMFM/GMFCS-based Motor Development Curves.228 It
describes the principles of common treatment options which
can be considered in an interdisciplinary setting. The goal is to
provide parents and caretakers, physicians and therapists
with a means to plan treatments and interventions within the
multidisciplinary treatment approach and to help answer
questions concerning: What? When? How much? How long?
At the same time the limitations of a graphical conclusion
have to be considered: The graph is not designed to show
a predictable and detailed course of development for the
individual child and it does not serve as a fixed protocol for the
interdisciplinary treatment team.
The basal (green) curve represents all functional therapies.
It forms the foundation to which all other therapies can be
added on demand. These other therapies are coded with other
colours (bright green¼ orthoses/aids, yellow¼ oral medica-
tion, orange¼ Botulinum toxin, red¼ intrathecal baclofen,
blue¼ orthopaedic surgery):
Functional therapies (basal, green line): support of motor devel-
opment in children with CP is the continuous principle of care.
Besides adaptive support of motor development, negative
alterations can be uncovered and addressed as they appear by
e.g. short term intensification of treatment blocks.135,229–231
Orthoses/aids (bright green line): goal and therapeutic benefit need
to be defined ideally in conjunction with the orthotist, paediatric
neurologist, and paediatric orthopaedic. Improvement of func-
tion in daily activity, but also prevention of structural defor-
mities are the two most important therapeutic goals.132,232
Ambulatory aids are essential for participation in daily activities.
Oral medication (yellow line): oral, anti-spasticity medication
aims to generally reduce muscle tone in children with CP. Due
to frequent habituation to applied dosages, treatment often is
limited to short- or medium-term benefit. Generalised
systemic side effects frequently limit the application of
adequate dosages for a sufficient tone reduction.233,234
Botulinum toxin (orange line): its indication has been applied to
all grades of severity in children with CP (GMFCS I–V). As
a focal treatment for a non-focal disease it ranges from focal
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Fig. 1 – CPGraph treatment modalities – gross motor function.
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substance may occur when dose recommendations and dose
modifiers are not regarded.45,70
Intrathecal baclofen (red line): the indication for ITB has been
established for GMFCS levels IV and V, rarely III. The moni-
toring needs to be performed in an experienced centre in order
to minimize the occurrence of systemic adverse events or
complications.235–238
Orthopaedic surgery (blue line): developmental paediatrician,
paediatric neurologist, and rehabilitation specialist often are the
initial treating physicians in children with CP. To optimize
motor development it is essential to include paediatric ortho-
paedic surgeons into the therapeutic team as early as possible.
Depending on the severity of CP frequent consultations or
shared evaluations of the patient should be performed. GMFCS
levels IV and V need to be monitored as early as possible for
‘‘hips at risk’’.16,111 The correct indication for surgery at the right
time has to be established in the future with respect to GMFCS
level, long-term outcome, effects and side effects on the levels of
body structure and function as well as activity and participation.Conflicts of interest
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